MODAG: Positive Phase 1 Results of Potential New Parkinson’s Drug

MODAG: Positive Phase 1 Results of Potential New Parkinson’s Drug
The German biotech company 'MODAG' announced this week that they have completed the first part (Phase 1) of their clinical trial of a new Parkinson's drug. This new drug, called "Anle138b", is a therapy that enters the brain and targets the protein alpha-synuclein. In Parkinson's, alpha-synuclein starts to mis-fold and clump together and it is believed that in this state ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-08-10